---
title: "ARPA-H Initiates $63 Million AI Project for Heart Failure Management"
id: "news-news-fierce-healthcare-d48ec708921677db582f5991"
canonical_url: "https://medichelpline.com/news/news-news-fierce-healthcare-d48ec708921677db582f5991"
content_type: "medical_news_article"
category: "Industry"
source_name: "Fierce Healthcare"
source_url: "https://www.fiercehealthcare.com/ai-and-machine-learning/arpa-h-launches-63m-cardiovascular-ai-initiative-naming-updoc-tempus-ai"
published_at: "2026-09-11T21:20:48.753Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# ARPA-H Initiates $63 Million AI Project for Heart Failure Management
## Metadata & Source Attribution
- **Canonical URL:** https://medichelpline.com/news/news-news-fierce-healthcare-d48ec708921677db582f5991
- **Category:** [Industry](https://medichelpline.com/news/industry.md)
- **Reporting Source:** Fierce Healthcare
- **Original Source URL:** [Read Original Article](https://www.fiercehealthcare.com/ai-and-machine-learning/arpa-h-launches-63m-cardiovascular-ai-initiative-naming-updoc-tempus-ai)
- **Published At:** 2026-09-11T21:20:48.753Z
## Executive Summary & Key Highlights
- ARPA-H has launched a $62.7 million initiative named ADVOCATE to create AI systems for **heart failure** treatment. - The project aims to develop autonomous AI agents that monitor patients, provide care, and alert clinicians as necessary. - ARPA-H will work with the FDA to set a regulatory framework for new autonomous clinical AI systems, targeting an FDA approval within two years. - Selected partners include **Atman Health**, **Tempus AI**, and **UpDoc**, tasked with building patient-facing AI agents to improve cardiovascular outcomes. - The initiative aims for significant cost savings and improved patient outcomes in a field where cardiovascular disease remains a leading cause of death in the U.S.
## In-Depth Reporting & Editorial Analysis
## ARPA-H Launches $63 Million Initiative for AI in Heart Failure Care The Advanced Research Projects Agency for Health (**ARPA-H**) has announced a substantial investment of **$62.7 million** for an initiative designed to create **AI** systems that will enhance care for patients suffering from **heart failure**. Named the **Agentic AI-Enabled Cardiovascular Care Transformation** (ADVOCATE), this program seeks to develop a **patient-facing AI** capable of monitoring heart failure patients continuously, providing necessary care autonomously, and escalating issues to healthcare providers when required. ## Program Goals and Structure The ADVOCATE initiative aims to produce an autonomous digital member of the healthcare team that will function effectively between patient visits. The program involves building clinical AI systems that include both a patient-facing agent and a supervisory AI system, allowing for robust monitoring and care management. As part of the program, participating teams are expected to submit an **FDA authorization package** within **two years**. Close collaboration with the **FDA** is pivotal to establish regulatory standards for this new class of clinical AI, which serves as an evolution beyond previously approved predictive AI technologies. ### Coordination with Key Institutions ARPA-H intends to create a framework that encompasses shared evaluation standards, interoperability requirements, and pathways for reimbursement in the healthcare system. To ensure the program's efficacy and safety, **Johns Hopkins University Applied Physics Laboratory** (JHU/APL) has been engaged as an external evaluation partner to validate the program's outcomes. ## Addressing Cardiovascular Care Gaps The initiative aims to tackle significant deficiencies in **cardiovascular care**, particularly in underserved regions. Current statistics suggest nearly half of U.S. counties do not have access to a cardiologist. Furthermore, the nation spends close to **$500 billion** annually on heart disease while experiencing subpar cardiovascular health outcomes relative to other developed countries. Each year, over **200,000 Americans die** from preventable circumstances surrounding cardiovascular disease, the leading cause of death in the United States. Dr. **Haider Warraich**, the ADVOCATE Program Manager and a cardiologist, remarked on the project's potential impact, noting that the obstacles to healthcare delivery often do not stem from medical capabilities but from access to clinical guidance. He emphasized that the ADVOCATE project seeks to develop technology that acts as a clinician extender—an autonomous system adept at assessing patient treatment needs, executing care, and engaging healthcare teams as necessary. ## Expected Outcomes and Funding ARPA-H has allocated up to **$33.7 million** for the first year of this four-year program. Successful implementation of ADVOCATE is projected to save lives, reduce avoidable hospitalizations, and potentially yield economic savings estimated at **$28 billion** annually across the heart failure population, according to agency officials. ### Development of AI Agents Three health technology companies have been selected to develop these patient-centric clinical AI agents: **Atman Health**, **Tempus AI**, and **UpDoc**. Each company will focus on creating a clinical AI agent that functions as a virtual component of care teams and will be responsible for monitoring patients between visits, adjusting medications, and referring complex cases to human clinicians when necessary. - **Atman Health** received up to **$7.7 million** to build its clinical AI system based on a proven clinical decision framework. This system will include advanced voice-interaction capabilities for user engagement. - **Tempus AI**, awarded up to **$9.5 million**, will enhance its existing **Olivia** health app to incorporate continuous monitoring and sophisticated clinical analysis. - **UpDoc** will get up to **$9.2 million** to create a comprehensive AI solution that continuously evaluates patient data, facilitating clinical decision-making while maintaining oversight from medical professionals. ## Regulatory Pathways and Implementation The ADVOCATE initiative also includes a defined pathway for navigating the FDA approval process, emphasizing a crucial timeline of **39 months** for transitioning from prototype development to clinical application. This pathway encompasses independent evaluations, performance benchmarking with practicing cardiologists, and large-scale scalability trials. The program’s implementation will involve collaboration with **Duke University** and **Kaiser Permanente** for real-world testing and adaptation across multiple healthcare systems. Duke will spearhead a consortium focused on validating the ADVOCATE agents across various health settings, while Kaiser Permanente will develop strategies to effectively integrate AI solutions into existing workflows. ### Future Aspirations The broader aim of the ADVOCATE initiative is to reshape the delivery of care for heart failure, ultimately improving patient outcomes while addressing the critical healthcare gaps within the current system. Dr. **Ankeet Bhatt**, leading the Kaiser Permanente project, expressed the hope that this innovative application of AI could significantly narrow care gaps and enhance the management of heart failure, leveraging the best available medical evidence to achieve better patient outcomes. In conclusion, ARPA-H's ADVOCATE program represents a potentially transformative leap in using AI to enhance cardiovascular care, showcasing an essential move towards more integrated and effective healthcare delivery solutions.
## Navigation
- [← Back to Industry News](https://medichelpline.com/news/industry.md)
- [← All Medical News Categories](https://medichelpline.com/news.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.